Pooling patents for HIV drugs: A paradigm shift
Nirav Bhatt is an LLM candidate at Osgoode Hall Law School. According to a report, AIDS, which is caused due to Human immunodeficiency virus (HIV)
October 16, 2009
No Comments
Category: Pharmaceutical Drugs
Process or Product? Recent Product-by-Process Case May Pose Problems for Innovators
The U.S. Court of Appeals for the Federal Circuit recently ended much of the controversy surrounding product-by-process claims in Abbott Laboratories v. Sandoz, Inc., but
September 9, 2009
No Comments
Should Exclusivity Periods be Tailored to Technology?
On Friday, July 31st, the United States House Committee on Energy and Commerce approved “America’s Affordable Health Choices Act” by a narrow three-vote margin. The
August 27, 2009
No Comments
Federal Court Ruling Upholds Data Protection Period for Research-Based, Innovative Drug Companies
The period of data protection allocated to research-based, innovative drug companies is a hotly debated topic in the pharmaceutical industry and beyond. This period of protection
August 7, 2009
2 Comments
The Efficacy Standard – India’s New Patentability Criteria
Nigel D’Souza is a JD Candidate at Osgoode Hall Law School. I have been researching at Human Rights Law Network for over a month now
August 3, 2009
1 Comment
Blakes Seminar Shows That Intellectual Property is a Hot Topic in Canada
Intellectual property is an area of law that has more impact on our daily lives than many people realize. At a seminar series held at
July 14, 2009
No Comments